Sun Pharma is the biggest loser on the Nifty as it missed estimates. Also, the management gave a very conservative guidance of 8-10 percent growth in consolidated sales for FY17. A bullish SP Tulsian of sptulsian.com gave a support price of Rs 700.
first published: May 31, 2016 03:47 pm
A collection of the most-viewed Moneycontrol videos.

New Year Party Or Year-End Blues? Bulls In Focus| Top Stock Bets & 2026 Outlook| Opening Bell Live

Nifty Trades in a Narrow 100-Point Range on 2025’s Final F&O Expiry | Closing Bell Live

Small-Caps & Risk: What Investors Often Miss

Nifty’s Best Case Target & Top Stock Bets For 2026| IPO Wave Set To Get Bigger| Opening Bell Live
You are already a Moneycontrol Pro user.

